Absci's hair-loss drug is well tolerated in first 3 cohorts Absci plans preliminary ABS-201 safety and PK data in H1 2026 and interim proof-of-concept data in H2 after ending 2025 with $144.3M.

#ABSI Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

www.stocktitan.net/news/ABSI/absci-reports-...

#ABSI Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

www.stocktitan.net/news/ABSI/absci-reports-...

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia Absci (Nasdaq: ABSI) announced dosing of the first healthy volunteers in the Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia (AGA).The randomized, double-blind, placebo-controlled study will enroll up to 227 participants, assess safety, tolerability, PK/PD, immunogenicity and efficacy (TAHC, TAHW, TAHD), and includes SAD (4–6 IV dose groups) and MAD (3–4 SC dose groups) stages. Interim AGA data are expected in H2 2026. Absci plans to start Phase 2 in endometriosis in Q4 2026 with an interim endometriosis readout planned for H2 2027. A KOL seminar is scheduled for Dec 11, 2025.

#ABSI Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia

www.stocktitan.net/news/ABSI/absci-announce...

Here's my list of who could win...

1.) Biotechnology - train scientific foundation models for biology to automate drug/material discovery

Potential winners: #RXRX #DNA #SDGR #ABSI #TWST #ADPT

#ABSI #004479e4-5865-4513-a641-b8d814a75bf3 #earningscall-transcripts

Origin | Interest | Match

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results Absci (Nasdaq: ABSI) reported Q3 2025 results and program updates. Key financials: revenue $0.4M (Q3 2024: $1.7M), net loss $28.7M, and cash, cash equivalents & marketable securities $152.5M, which the company says is sufficient to fund operations into the first half of 2028.Clinical highlights: interim Phase 1 data for ABS-101 showed extended half-life and no serious adverse events. ABS-201 (anti-PRLR) will start a Phase 1/2a in Dec 2025 with a potential interim efficacy readout in H2 2026 and an expanded Phase 2 in endometriosis expected in Q4 2026 with potential POC in H2 2027. Company to host a KOL seminar on Dec 11, 2025.

#ABSI Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/ABSI/absci-reports-...

#ABSI collaborating w/ #ORCL + #AMD on AI-powered drug discovery.

Personally, I think this may be the most undervalued vertical of the AI Boom. Lots of really interesting names in the biotech AI space that remain pretty depressed.

2.5µs GPU Latency: Absci's AI Drug Discovery Platform Gets Supercharged by Oracle Cloud and AMD Partnership Biotech firm Absci leverages Oracle Cloud Infrastructure and AMD's MI355X GPUs to enhance AI drug discovery platform, achieving 2.5µs inter-GPU latency for advanced biologics design.

#ABSI Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

www.stocktitan.net/news/ABSI/absci-accelera...

Absci Sales Fall 54 Percent | The Motley Fool

#ABSI #a268608c-c22b-4326-a999-94fabf06175b #data-news

Origin | Interest | Match

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target Absci (NASDAQ:ABSI) and Almirall (BME:ALM) have expanded their AI Drug Discovery collaboration by adding a second dermatology target. This expansion follows successful delivery of AI-designed antibody leads against the first difficult-to-drug target from their November 2023 collaboration.The partnership combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to develop novel therapeutics for skin diseases. Absci could receive up to $650 million in various milestone payments plus royalties, while being responsible for designing and validating therapeutic candidates. Almirall will lead preclinical and clinical development programs.

#ABSI Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

www.stocktitan.net/news/ABSI/almirall-and-a...

Absci Announces Pricing of Public Offering of Common Stock Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-designed therapeutics, has announced the pricing of its public offering of 16,670,000 common stock shares at $3.00 per share. The offering is expected to generate gross proceeds of approximately $50 million before deductions.The company has granted underwriters a 30-day option to purchase up to 2,500,500 additional shares. The proceeds will fund internal program advancement, investment in their Integrated Drug Creation™ platform, and general corporate purposes. The offering, managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen, is expected to close around July 25, 2025.

#ABSI Absci Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/ABSI/absci-announce...

Absci Announces Proposed Public Offering of Common Stock Absci (NASDAQ: ABSI), a clinical-stage biopharmaceutical company leveraging generative AI for therapeutic development, has announced a proposed public offering of $50 million in common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million in shares.The offering will be managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities as joint book-running managers. Proceeds will support Absci's internal program development, platform investment, and general corporate purposes. The offering will be made through an effective shelf registration statement previously filed with the SEC.

#ABSI Absci Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/ABSI/absci-announce...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish moving average convergence divergence crossovers, Thu May 15th - #NCT #ABSI #BVS #CGEN #HRZN #IMKTA #JBSS #LILA #MNRO #OESX #ZIP #SQNS #RGR #MBC #KLG #GLP #CMRE #AZUL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Absci Achieves Major Milestone: First Human Trial Begins, Pipeline Expands with AI-Designed Antibodies Absci initiates first-in-human trial for ABS-101, advances AI-designed antibody pipeline, and reports $134M cash position. See interim data timeline and growth metrics.

#ABSI Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/ABSI/absci-reports-...

Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential Absci's AI-designed ABS-101 launches Phase 1 trial for IBD with potential quarterly dosing advantage. Key interim data expected H2 2025. Learn trial details.

#ABSI Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

www.stocktitan.net/news/ABSI/absci-announce...

Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results Absci (NASDAQ: ABSI) reported its Q4 and full year 2024 financial results, highlighting significant progress in its AI Integrated Drug Creation platform. The company secured a $20 million strategic investment from AMD and established new partnerships with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center.Key pipeline updates include ABS-101's advancement toward Phase 1 clinical studies in H1 2025, and ABS-201's development for androgenic alopecia targeting a potential U.S. market of 80 million individuals. The company's financial position shows Q4 2024 revenue of $0.7 million and a net loss of $29.0 million. Full-year 2024 results include revenue of $4.5 million and a net loss of $103.1 million.With $112.4 million in cash and investments as of December 31, 2024, Absci expects to fund operations into the first half of 2027.

#ABSI Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

www.stocktitan.net/news/ABSI/absci-reports-...

32. Jahrestagung 7.-8.03.2025 – ABSI Arbeitsgemeinschaft Bayerischer Solar-Initiativen

Am 7 & 8 März Treffen der Solar Begeisterten Wie geht es weiter wenn es eine neue GroKo gibt ? Anmeldung noch möglich www.solarinitiativen.de/32-jahrestag... #solar #simon #solarstrom #solarpark #allgäu #wilpoldsried #solariniative #absi #photovoltaik #windenergie #akku #h2 #wasserstoff

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ALK, #AI, #RXRX, #TDOC, #ABSI

#OptionFlow #OptionsTrading #Trading

Absci Teams Up with Owkin to Supercharge AI Drug Discovery in Cancer and Immunology Strategic AI partnership combines Absci's drug creation platform with Owkin's predictive models to accelerate novel therapeutic development in oncology and immunology.

#ABSI Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

www.stocktitan.net/news/ABSI/absci-and-owki...

Absci #ABSI shares rises more than 50% in premarket after AMD to invest $20 million in it

Absci Secures $20M AMD Investment, Strategic AI Drug Discovery Partnership to Accelerate Innovation AMD invests in Absci through PIPE deal, providing advanced Instinct accelerators to power AI-driven antibody design. Partnership aims to enhance drug discovery capabilities.

#ABSI Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

www.stocktitan.net/news/ABSI/absci-and-amd-...

Absci Partners with Invetx to Revolutionize Animal Health with AI-Powered Antibody Platform Absci's generative AI technology joins forces with Invetx to develop innovative Half-Life Extension platform for veterinary therapeutics, targeting major canine health markets.

#ABSI Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

www.stocktitan.net/news/ABSI/absci-and-inve...